Results 61 to 70 of about 635,464 (240)

Monographs on drugs which are frequently analyzed in therapeutic drug monitoring [PDF]

, 2017
In addition to the monographs which have been published in the past 4 years by the working group "Drug Monitoring” of the Swiss Society of Clinical Chemistry (SSCC) [1-4], new monographs have been written.
Buhl, Daniela, Eap, Chin Bin, Fathi, Marc, Jöchle, Wolfgang, Magnin, Jean-Luc, Rentsch, Working group "Drug Monitoring” of the SSCC: Katharina, Thormann, Wolfgang, Werner, Dominique   +7 more
core  

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Respiratory complex I‐mediated NAD+ regeneration regulates cancer cell proliferation through the transcriptional and translational control of p21Cip1 expression by SIRT3 and SIRT7

Molecular Oncology, EarlyView.
NAD+ regeneration by mitochondrial complex I NADH dehydrogenase is important for cancer cell proliferation. Specifically, NAD+ is necessary for the activities of NAD+‐dependent deacetylases SIRT3 and SIRT7, which suppress the expression of p21Cip1 cyclin‐dependent kinase inhibitor, an antiproliferative molecule, at the translational and transcriptional
Masato Higurashi, Kazunori Mori, Hidetsugu Nakagawa, Momoko Uchida, Fumihiro Ishikawa, Motoko Shibanuma   +5 more
wiley   +1 more source

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

Molecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam, Megan E. Roche, Zhao Lin, Diana Whitaker‐Menezes, Victor Diaz‐Barros, Eurico Serrano, Maria Paula Martinez Cantarin, Nancy J. Philp, Atrayee Basu Mallick, Ubaldo Martinez‐Outschoorn   +9 more
wiley   +1 more source

Cyclosporine measurement by FPIA, PC-RIA, and HPLC following liver transplantation [PDF]

, 1990
The factors affecting CyA dosing and kinetics in LT patients are complex, and have been thoroughly investigated and reviewed. Plasma or WB CyA concentration monitoring remains the best method presently available for adjusting CyA dosage in LT patients in
Burckart, GJ, Diven, W, Jain, A, Starzl, TE, Venkataramanan, R   +4 more
core  

Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide [PDF]

, 2013
Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increasing seriously. Repaglinide is a glucose reducing agent that predominantly reduces post-prandial glucose.
Bonakdaran, S., Hezarkhani, S., Marjani, A., Rajabian, R., Shahini, N.   +4 more
core   +1 more source

Enhancing patient engagement in cancer research: a focus on patient‐centric approaches to scientific discovery

Molecular Oncology, EarlyView.
Patient engagement involves actively including patients in healthcare decisions and research to ensure care and studies align with their needs. This approach improves outcomes, trust, and communication while fostering collaboration between patients and professionals.
Estela Cepeda, Marina Reguero, Vanesa Abón, Marta Puyol   +3 more
wiley   +1 more source

2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs [PDF]

, 2016
This report represents a scientific and working clinical consensus statement on seizure management in dogs based on current literature and clinical expertise.
Bunch SE, Bunch SE, Cheuk DK, Cunningham JG, Dayrell‐Hart B, Durkes TE, Dyer KR, E.E. Patterson, Farnbach GC, Farnbach GC, Forrester SD, Frey HH, Gaskill CL, Gaskill CL, H.A. Volk, Jacobs G, Jennings PB, K. Muñana, Kantrowitz LB, M. Berendt, M. Podell, March PA, Masuda Y, Nichols ES, Patterson E, Pearce L, Pedersoli WM, Perrucca E, Poffenbarger EM, Ravis WR, S.R. Platt, Schwartz‐Porsche D, Schwartz‐Porsche D, Steinberg M, Thurman GD, Trepanier LA, Trepanier LA, W. Löscher   +37 more
core   +2 more sources

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

Molecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini, Giada Mele, Marika Attili, Maria Rita Assenza, Fulvio Saccoccia, Francesca Sardina, Cinzia Rinaldo, Roberto Massari, Nicola Tirelli, Alfredo Pontecorvi, Fabiola Moretti   +10 more
wiley   +1 more source

Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. [PDF]

, 2020
Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric ...
Kraft, Walter K., Lam, Edwin, Lien, Yi Ting Kayla, Piraino, Beth, Schmidt, Stephan, Vozmediano, Valvanera, Zhang, Jingjing   +6 more
core   +1 more source